primary results of the SOUL trial of oral semaglutide (Rybelsus, Novo Nordisk) to reduce CV events in people with diabetes with atherosclerotic CVD and/or chronic kidney disease; trial to evaluate ...

21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomised trial compared oral semaglutide to placebo as an ...

21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomised trial compared oral semaglutide to placebo as an ...

The big question for Lilly is whether the data are strong enough to fend off the challenge from Novo Nordisk’s once-weekly GLP-1 agonist Ozempic (semaglutide ... SOUL trial in 9,642 adults ...

But becoming a different person, while exciting, weighs on your soul. It can sometimes ... as shown in a randomized control trial investigating semaglutide discontinuation and a randomized ...

These animals are often called soul pets or heart pets, and while the experience is deeply personal, those who have met their soul pet often describe it as life-changing. Whether they came to you ...

Research reveals semaglutide's effectiveness in decreasing alcohol consumption and cravings, highlighting its potential for ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...

Study: Once-Weekly Semaglutide in Adults With Alcohol Use Disorder A Randomized Clinical Trial. Image Credit: simon jhuan/Shutterstock.com A recent JAMA Psychiatry study investigates the ...